Tags

Type your tag names separated by a space and hit enter

Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
Oncotarget 2017; 8(30):49084-49092O

Abstract

OBJECTIVES

To evaluate the clinical efficacy and toxicity of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC).

RESULTS

All patients completed definitive radiotherapy and 74 (85.1%) patients administrated platinum-based chemotherapy. The median radiation dose was 50.4Gy to PTV and 64.4 Gy simultaneously to the PGTV. The overall response rate (ORR) was 57.5% (50/87). The median duration of follow up was 24.6 months. The 1, 2, 3-year local control rate was 79.0%, 66.1%, and 60.5%, respectively. The 1, 2, 3-year overall survival (OS) rate was 89.7%, 56.7%, and 30.6%, respectively. Subgroup analysis showed that the median OS in concurrent chemoradiation (CCRT) was much better than non-CCRT (35.7 vs. 26.4 months) (HR: 0.52, 95% CI: 0.32-0.95, P = 0.033). Twenty-two (25.3%) patients experienced acute grade 3 esophagitis and 10 (11.5%) experienced acute grade ≥ 3 radiation pneumonitis. There were 2 (2.6%) late grade 3 pulmonary toxicity and no late grade ≥ 3 esophageal toxicity was observed.

MATERIALS AND METHODS

A total of 87 patients with locally advanced NSCLC who received SIB-IMRT from Jan. 2009 to Dec. 2012 in our hospital were retrospectively analyzed. Male accounted for 88.5%, with a median age of 61 years old. The SIB-IMRT plans were designed to deliver 50.4-64.0 Gy in 28-33 fractions (1.8-2.1 Gy/fraction) to PTV while simultaneously delivering 60.0-74.3 Gy in 28-33 fractions (2.0-2.5 Gy/fraction) to PGTV.

CONCLUSIONS

SIB-IMRT, especially with concurrent chemotherapy, appears to be an effective and safe option to treat patients with locally advanced NSCLC. More prospective clinical studies should be warranted.

Authors+Show Affiliations

Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China.Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China.Department of Radiation Physics, Zhejiang Cancer Hospital, Hangzhou, 310022, China.Department of Radiation Physics, Zhejiang Cancer Hospital, Hangzhou, 310022, China.Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China.Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China.Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China.Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China. Zhejiang Provincial Key Laboratory of Radiation Oncology, Hangzhou, 310022, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28467775

Citation

Xu, Yujin, et al. "Simultaneous Integrated Boost Intensity-modulated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer in Chinese Population: a Retrospective Study." Oncotarget, vol. 8, no. 30, 2017, pp. 49084-49092.
Xu Y, Zheng X, Bai X, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. Oncotarget. 2017;8(30):49084-49092.
Xu, Y., Zheng, X., Bai, X., Li, P., Ma, H., Wang, J., ... Chen, M. (2017). Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. Oncotarget, 8(30), pp. 49084-49092. doi:10.18632/oncotarget.17094.
Xu Y, et al. Simultaneous Integrated Boost Intensity-modulated Radiotherapy for Locally Advanced Non-small Cell Lung Cancer in Chinese Population: a Retrospective Study. Oncotarget. 2017 Jul 25;8(30):49084-49092. PubMed PMID: 28467775.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study. AU - Xu,Yujin, AU - Zheng,Xiao, AU - Bai,Xue, AU - Li,Pu, AU - Ma,Honglian, AU - Wang,Jin, AU - Hu,Xiao, AU - Chen,Ming, PY - 2017/03/03/received PY - 2017/03/31/accepted PY - 2017/5/4/pubmed PY - 2018/4/24/medline PY - 2017/5/4/entrez KW - integrated boost intensity-modulated radiotherapy KW - local control KW - non-small cell lung cancer KW - overall survival SP - 49084 EP - 49092 JF - Oncotarget JO - Oncotarget VL - 8 IS - 30 N2 - OBJECTIVES: To evaluate the clinical efficacy and toxicity of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). RESULTS: All patients completed definitive radiotherapy and 74 (85.1%) patients administrated platinum-based chemotherapy. The median radiation dose was 50.4Gy to PTV and 64.4 Gy simultaneously to the PGTV. The overall response rate (ORR) was 57.5% (50/87). The median duration of follow up was 24.6 months. The 1, 2, 3-year local control rate was 79.0%, 66.1%, and 60.5%, respectively. The 1, 2, 3-year overall survival (OS) rate was 89.7%, 56.7%, and 30.6%, respectively. Subgroup analysis showed that the median OS in concurrent chemoradiation (CCRT) was much better than non-CCRT (35.7 vs. 26.4 months) (HR: 0.52, 95% CI: 0.32-0.95, P = 0.033). Twenty-two (25.3%) patients experienced acute grade 3 esophagitis and 10 (11.5%) experienced acute grade ≥ 3 radiation pneumonitis. There were 2 (2.6%) late grade 3 pulmonary toxicity and no late grade ≥ 3 esophageal toxicity was observed. MATERIALS AND METHODS: A total of 87 patients with locally advanced NSCLC who received SIB-IMRT from Jan. 2009 to Dec. 2012 in our hospital were retrospectively analyzed. Male accounted for 88.5%, with a median age of 61 years old. The SIB-IMRT plans were designed to deliver 50.4-64.0 Gy in 28-33 fractions (1.8-2.1 Gy/fraction) to PTV while simultaneously delivering 60.0-74.3 Gy in 28-33 fractions (2.0-2.5 Gy/fraction) to PGTV. CONCLUSIONS: SIB-IMRT, especially with concurrent chemotherapy, appears to be an effective and safe option to treat patients with locally advanced NSCLC. More prospective clinical studies should be warranted. SN - 1949-2553 UR - https://www.unboundmedicine.com/medline/citation/28467775/Simultaneous_integrated_boost_intensity_modulated_radiotherapy_for_locally_advanced_non_small_cell_lung_cancer_in_Chinese_population:_A_retrospective_study_ L2 - http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=17094 DB - PRIME DP - Unbound Medicine ER -